Y-mAbs Therapeutics, Inc. (YMAB)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Michael Rossi | CEO, President & Director | 1.1M | -- | 1971 |
| Mr. Thomas Gad | Founder, Chief Business Officer & Vice Chairman | 911.89k | -- | 1970 |
| Mr. Peter P. Pfreundschuh CPA | Executive VP, CFO & Treasurer | 594.25k | -- | 1969 |
| Mr. Joris Wiel Jan Wilms | Senior VP & COO | -- | -- | 1974 |
| Dr. Torben Lund-Hansen M.Sc., Ph.D. | Senior VP & CTO | -- | -- | 1951 |
| Ms. Courtney Dugan | Vice President of Investor Relations | -- | -- | -- |
| Mr. John W. LaRocca Esq. | Senior VP, General Counsel, Secretary & Chief Legal Officer | -- | -- | 1965 |
| Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Development Officer & Chief Medical Officer | -- | -- | 1948 |
| Mr. Doug Gentilcore | Senior VP & Head of DANYELZA Business Unit | -- | -- | 1980 |
| Ms. Natalie Tucker | Senior VP & Radiopharmaceutical Business Unit Head | -- | -- | -- |
Y-mAbs Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 104
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Corporate Governance
Upcoming Events
August 11, 2025 at 12:30 PM UTC - August 15, 2025 at 12:30 PM UTC
Y-mAbs Therapeutics, Inc. Earnings Date
Recent Events
September 26, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission